Expression of stromal‐cell‐derived factor‐1 (SDF‐1): a predictor of ischaemic stroke?

Wurster, Thomas; Stellos, Konstantinos; Geisler, Tobias; Seizer, Peter; Andía, Marcelo E.; Schuster, Andreas; May, Andreas E.; Melms, Arthur; Gawaz, Meinrad; Bigalke, Boris

doi:10.1111/j.1468-1331.2011.03527.x

Cited by 23 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Controversies data regarding CXCL12 levels in patients with stroke had been reported. Consistent with our results, Kim et al [13] reported that serum CXCL12 levels were higher in acute-stage stroke patients compared with the normal control group, but Wurster et al [5] found no significant difference. Our findings of a linear association between serum CXCL12 and infarct volume stand in contrast to a previous report showing a moderately inversely (r = -0.49) correlated with baseline diffusionweighted imaging lesion volumes (P \ 0.04) [9].…”

Section: Discussionsupporting

confidence: 93%

“…The SDF-1a-CXCR4 interaction has also been reported to play a role in neuroprotection after stroke [25]. However, SDF-1a has been implicated in neuroinflammation after ischemic stroke [26], and its level may be correlated with stroke severity [5]. Similarly, we found that there a significant positive trend between serum CXCL12 levels and Hs-CRP (r = 0.202, P = 0.006).…”

Section: Discussionmentioning

confidence: 56%

“…However, the role of CXCL12 in patients with AIS had controversies [4,5,9,10]. Gu et al [11] reported that elevated circulating CXCL12 levels at admission are strongly associated with the future recurrence of ischemic stroke in Chinese patients with AIS and Schutt et al [4] found that plasma CXCL12 levels was a predictor of future stroke.…”

Section: Introductionmentioning

confidence: 97%

“…CXCL12 plays a pivotal role in angiogenesis and the regeneration ofi schemic tissue through the regulation of hematopoietic progenitor cells and is upregulated at the sites of vascular injury and platelet activation [5]. After ischemic stroke, CXCL12 mediates the inflammatory response by recruitment of neural progenitor cells and the mobilization of bone marrow-derived progenitor cells for tissue regeneration and neovascularization [6].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke

et al. 2015

View full text Add to dashboard Cite

The aim of this study was to investigate the potential diagnostic and prognostic role of CXC chemokine ligand-12 (CXCL12) in Chinese patients with acute ischemic stroke (AIS). All consecutive patients with first-ever AIS from January 2014 to August 2014 were recruited to participate in the study. CXCL12 and NIH Stroke Scale were measured at the time of admission. Short-term functional outcome was measured by modified Rankin scale 3 months after admission. Multivariate analyses were performed using logistic regression models. Receiver operating characteristic (ROC) curve was used to evaluate the accuracy of serum CXCL12 in diagnosing stroke and prognosing functional outcome. From 375 screened patients, a total of 288 patients with first-ever AIS were included in this study. Based on the ROC curve, the optimal cutoff value of serum CXCL12 levels as an indicator for auxiliary diagnosis of AIS was projected to be 3.5 ng/mL, which yielded a sensitivity of 88.1 % and a specificity of 73.5 %, with the area under the curve at 0.907 (95 % CI 0.882-0.932). In multivariate analysis, there was an increased risk of unfavorable outcome associated with serum CXCL12 levels ≥7.6 ng/mL (OR 4.356, 95 % CI 2.993-7.132, P < 0.0001) after adjusting for possible confounders. Our study demonstrated that elevated serum CXCL12 level at admission was an independent diagnostic and prognostic marker in patients with AIS.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 56%

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Serum CXCL12 Levels as a Novel Predictor of Future Stroke Recurrence in Patients with Acute Ischemic Stroke

Liu

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

Previous studies had shown that CXC chemokine ligand-12 (CXCL12) plays a significant role in animal models of ischemic stroke, but its role in human stroke is unclear. The aim of this study was to test the relationship between elevated serum circulating CXCL12 levels and the 1-year stroke recurrence in Chinese patients with acute ischemic stroke (AIS). All consecutive patients with first-ever acute ischemic stroke from January 2011 to September 2013 were recruited to participate in the study. Serum levels of CXCL12 and National Institute of Health Stroke Scale (NIHSS) were measured at the time of admission. Logistic regression analysis was used to evaluate the stroke recurrence according to serum CXCL12 levels. Receiver operating characteristic (ROC) curve was used to evaluate the accuracy of serum CXCL12 in predicting stroke recurrence. Clinical follow-up was performed at 1 year. In our study, 248 patients finished the 1-year follow-up. At 1-year follow-up, 31 patients had a recurrence ischemic stroke. The median CXCL12 levels were significantly higher in those who sustained a recurrence ischemic stroke compared with those who did not [24.2 ng/mL (IQR 15.4-33.7) vs 6.5 ng/mL (IQR 3.4-10.2); Z = 8.258, P < 0.0001]. In multivariate analysis, there was an increased risk of stroke recurrence associated with serum CXCL12 levels ≥12.15 ng/mL (OR 9.122, 95 % CI 6.103-15.104) after adjusting for above possible confounders. The time to recurrence stroke distribution between patients with baseline CXCL12 levels ≥12.15 ng/mL and those with baseline CXCL12 levels <12.15 ng/mL were significantly different (P < 0.0001, log-rank test). Elevated circulating CXCL12 levels at admission are strongly associated with the future recurrence of ischemic stroke in Chinese patients with AIS. Further studies are warranted to confirm this association and define the role for CXCL12 as a novel predictor biomarker for stroke recurrence.

show abstract

Platelet Chemokines in New Modes of Action

Chatterjee

Gawaz

2017

Cardiac and Vascular Biology

View full text Add to dashboard Cite

Expression of stromal‐cell‐derived factor‐1 (SDF‐1): a predictor of ischaemic stroke?

Abstract: Platelet SDF-1 surface expression did not show any significant difference in patients with TIA and ischaemic stroke compared with patients with NI events. Thus, single biomarker evaluation of platelet SDF-1 surface expression is not helpful to predict ischaemic stroke.

Cited by 23 publications

References 35 publications

The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke

The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke

Serum CXCL12 Levels as a Novel Predictor of Future Stroke Recurrence in Patients with Acute Ischemic Stroke

Platelet Chemokines in New Modes of Action

Contact Info

Product

Resources

About